Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that 5alpha-reductase type 1 localizes specifically to sebaceous glands in both normal and acne follicles, suggesting its role in sebum regulation.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

In this study, 4-(4-(phenylaminocarbonyl)benzoyl) benzoic acid exhibited the strongest inhibitory activity against the human type 2 steroid 5α-reductase isozyme among the compounds tested.

In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.

This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This study suggests that in human osteoblast-like cells, the 5alpha-reductase type 1 isozyme predominantly catalyzes the conversion of testosterone to DHT, which may play a role in bone homeostasis.

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

This study found that several synthesized compounds were potent inhibitors of human steroid 5alpha-reductase type 2 and reduced prostate weights in treated rats, with compound 15 showing promise for potency in humans.

This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This study found that 5α–reductase activity is higher in infrainfundibular keratinocytes compared to interfollicular epidermal keratinocytes, suggesting a potential role in acne-related follicular changes.

This study found that specific steroids, particularly 5 and 7b, decreased growth of prostate and seminal vesicles and bound to the androgen receptor, showing comparable pharmacological activity to finasteride.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.

This study found no significant associations between the polymorphisms of SRD5A1 and SRD5A2 genes and androgenetic alopecia, clinical types of baldness, or response to finasteride in Koreans.